Ebolaviruses

Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union

Retrieved on: 
Monday, November 11, 2019
Infectious diseases, Biotechnology, Pharmaceutical, Health, Infectious diseases, Health, Medicine, Ebolaviruses, Ebola, Biological weapons, Tropical diseases, Zoonoses, Food and Drug Administration, Priority review, Zaire ebolavirus, Ebola virus disease

The approval is based on data submitted to the European Medicines Agency for accelerated assessment in March 2019.

Key Points: 
  • The approval is based on data submitted to the European Medicines Agency for accelerated assessment in March 2019.
  • ERVEBO is currently under Priority Review with the U.S. Food and Drug Administration (FDA) with a target action date of March 14, 2020.
  • The European Commissions marketing authorization of ERVEBO is the result of an unprecedented collaboration for which the entire world should be proud.
  • After recognizing the need and urgency for an Ebola Zaire vaccine, many came together across sectors to answer the global call for outbreak preparedness.

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

Retrieved on: 
Tuesday, August 6, 2019
Medicine, Medical specialties, Infectious diseases, Ebolaviruses, Biological weapons, Tropical diseases, Zoonoses, Ebola, Zaire ebolavirus, Vaccine, Ebola virus disease, Ebola vaccine

LONDON and WASHINGTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.

Key Points: 
  • LONDON and WASHINGTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.
  • The candidate vaccines, based on GSKs proprietary ChAd3 platform, were further developed by GSK, including the Phase II development for the Ebola Zaire vaccine.
  • Thomas Breuer, Chief Medical Officer of GSK Vaccines, said: These agreements with the Sabin Vaccine Institute are an important next step in the fight against Ebola and Marburg viruses.
  • The Sabin Vaccine Institute, a non-profit organization founded in 1993, is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.

UNICEF launches swift response as first Ebola cases and deaths confirmed in Uganda

Retrieved on: 
Thursday, June 13, 2019
Infectious diseases, Animal diseases, Veterinary medicine, Biological weapons, Tropical diseases, Zoonoses, Ebolaviruses, Ebola, Ebola virus disease, UGANDA, Zaire ebolavirus

KAMPALA, Uganda, NAIROBI, Kenya and NEW YORK, June 132019 /CNW/ -UNICEF haslaunched an emergency Ebola response plan in Uganda following the confirmation of the first three cases of the Ebola Virus Disease in the country over the past two days.

Key Points: 
  • KAMPALA, Uganda, NAIROBI, Kenya and NEW YORK, June 132019 /CNW/ -UNICEF haslaunched an emergency Ebola response plan in Uganda following the confirmation of the first three cases of the Ebola Virus Disease in the country over the past two days.
  • The boy's grandmother also died from the virus in Kasese district on Wednesday, where almost 400,000 children live.
  • UNICEF'sshift to itsresponsephase in Uganda follows months of preparedness and prevention effortsas Ebola cases increased inDRC.
  • UNICEF is intensifying its efforts to do so and minimize this outbreak's potentially devastating impact on childrenand communities at-large in Uganda."